【摘要】 目的比较吸入性环索奈德与布地奈德治疗轻中度哮喘的安全性。方法采用cot-hrane系统评价方法双人进行资料提取、分析、评价,筛选出符合评价标准的文献,并使用RevMan 5.0软件进行Meta分析。结果共纳入9项研究,合计3 094例轻中度哮喘患者。分析结果显示,环索奈德与布地奈德治疗轻中度哮喘的不良事件总发生例数、加重哮喘、上呼吸道感染、流感综合征、鼻炎、发声异常、咽炎、头痛、支气管炙、口干、乏力、失眠、关节疼痛、皮肤瘙痒、转氨酶升高、咳嗽等比较,均无统计学意义。结论吸入性环索奈德与布地奈德在治疗轻中度哮喘的安全性相似更多还原

【Abstract】 Objective To compare the safety of inhaled ciclesonide and budesonide in treating mild-moderate asthma.Methods The Cochrane systematic review method was adopted to conduct the data extract,analysis and evaluation for screening out the literatures according to the evaluation criteria by two persons.The meta-analysis was performed by using RevMan 5.0 software.Results Nine randomized controlled trials(RCTs)involving 3 094 cases of mild-moderate asthma were included.The Meta-Analysis results showed that there were no statistical differences between ciclesonide and budesonide in the total occurrence cases of adverse events,asthma aggravation,upper respiratory tract infections,flu syndrome,rhinitis,heterophonia,pharyngitis,headache,bronchitis,dry mouth,hypodynamia,agrypnia,arthrosis pain,skin itch,high aminotransferase,cough,et al.Conclusion The safety of inhaled ciclesonide and budesonide in treating mild-moderate asthma is similar.更多还原